Roche’s Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA’s Approval for Patients with HER2-Positive Breast Cancers

 Roche’s Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA’s Approval for Patients with HER2-Positive Breast Cancers

Roche’s Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA’s Approval for Patients with HER2-Positive Breast Cancers

Shots:

  • The approval is based on three P-III study (HannaH, SafeHER, PrefHER) results assessing Herceptin Hylecta (SC) + CT vs Herceptin (IV) + CT in neoadjuvant and adjuvant patients with HER2-positive early breast cancer
  • P-III HannaH, SafeHER, PrefHER study: pCR (absence of invasive cancer cells in breast) (45.4% vs 40.7%); mean level of trastuzumab (78.7mcg/ml vs 57mcg/ml); no new safety signals, tolerable
  • Herceptin Hylecta (trastuzumab and hyaluronidase-oysk, SC) based on Halozyme’s Enhanze drug delivery technology targeted for patients with HER2-positive early breast cancer

Click here to read full press release/ article | Ref: Roche | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post